Clinical Trial Update: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating glofitamab plus ibrutinib with obinutuzumab for mantle cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING